ESTRO 2024 - Abstract Book

S398

Brachytherapy - Urology

ESTRO 2024

[3] van Heerden, Laura, et al. "Accuracy of dwell position detection with a combined electromagnetic tracking brachytherapy system for treatment verification in pelvic brachytherapy." Radiotherapy and Oncology 154 (2021): 249-254.

[4] Kolkman-Deurloo, I., et al. "OC-0064 First clinical results of integrated EM tracking for pre-treatment verification in prostate BT." Radiotherapy and Oncology 158 (2021): S48-S49.

557

Digital Poster

Local salvage brachytherapy for recurrent prostate cancer: a mono-institutional experience.

Silvia Rodríguez Villalba 1 , Diana Guevara Barrera 1 , Jose Pérez- Calatayud 1,2 , Francisco Blazquez Molina 1 , MariaJose Pérez Calatayud 2 , Manuel Santos Ortega 1 1 Hospital Clínica Benidorm, Radiotherapy Department, Benidorm, Spain. 2 Hospital Universitario y Politécnico La Fe, Radiotherapy Department, Valencia, Spain

Purpose/Objective:

Local salvage therapies are offered to prostate cancer (PCa) patients with recurrent disease following primary radiation therapy with initial curative intent. Prostate re-irradiation is associated with potential urological and gastrointestinal toxicity depending on factors such as previous radiotherapy treatment received, total dose, interval from previous treatment , and toxicity. The decision of performing local salvage therapy must be very careful and strict, ensuring with the diagnostic techniques available today (multiparametric MRI (mpMRI), PSMA PET or choline PET), in the most approximate way possible, the exclusive existence of local prostate disease. One of treatments employed for local salvage is brachytherapy (BT). The results published in the literature with this technique, from both retrospective and prospective studies are not encouraging, and in series with 10 or more years of follow-up, it is only recommended by some international societies within the context of a clinical trial (1). We present the retrospective analysis of 16 patients rescued with low dose rate (LDR) and high dose rate (HDR) brachytherapy (BT).

Material/Methods:

We performed a retrospective analysis of 16 patients who underwent rescue BT between January 2005 and December 2021. Patients received 30 Gy in 3 fractions of 10 Gy over 3 implants, with an interval of 10 days between each implant with HDR, and 145 Gy with LDR with permanent 125 Iodine seeds. Dose was prescribed to the prostate, with a 2 mm isometric margin (except posteriorly, where no margin was applied) following ESTRO/EAU/EORTC recommendations as if it was a primary treatment (2,3)

Results: